Moleculin Biotech - MBRX

"We believe the findings provide important third-party validation of both the clinical and commercial potential of Annamycin," said Walter Klemp, Moleculin CEO. Read more on the findings, including a parallel survey of payers showing strong support for Annamycin filling a significant unmet need. https://bit.ly/4uhLqFg

In a recent independent market landscape assessment, surveyed oncologists reported high likelihood to prescribe Annamycin (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key drivers. Read more about the assessment: https://bit.ly/4uhLqFg

"These independent research findings are highly encouraging and reinforce the potential role we believe Annamycin can play in addressing one of the most difficult areas of AML treatment," said Walter Klemp, Chairman and CEO. Read more about the recent results from an independent market landscape assessment evaluating Annamycin in R/R AML: https://bit.ly/4uhLqFg

In a new Virtual Investor "What This Means" segment, Moleculin CEO Walter Klemp gives insight into why the 45-patient enrollment milestone is a critical step toward the trial’s interim data unblinding, which remains on track for mid-2026 and potentially a defining infection point for the Company. Watch here: https://bit.ly/45j8k6r

Moleculin today announced results from an independent market landscape assessment evaluating Annamycin in relapsed/refractory acute myeloid leukemia (R/R AML). The research demonstrated strong physician interest in Annamycin, with oncologists reporting an average likelihood-to-prescribe score of 6 out of 7. Read more: https://bit.ly/4uhLqFg

Moleculin today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor “What This Means” segment highlighting the Company's recent 45 subject enrollment milestone in the Phase 2B/3 MIRACLE trial. Watch the full segment here: https://bit.ly/45j8k6r